Melinta Therapeutics Inc.Find Ratings Reports
MELINTA THERAPEUTICS INC's gross profit margin for the second quarter of its fiscal year 2019 has increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the subsector when comparing revenue growth, but not when comparing net income growth. MELINTA THERAPEUTICS INC has weak liquidity. Currently, the Quick Ratio is 0.83 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 45.71% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY19||Q2 FY18|
|Net Sales ($mil)||15.96||12.02|
|Net Income ($mil)||-36.18||-55.78|
|Balance Sheet||Q2 FY19||Q2 FY18|
|Cash & Equiv. ($mil)||90.34||150.09|
|Total Assets ($mil)||440.37||514.65|
|Total Debt ($mil)||162.55||107.46|
|Profitability||Q2 FY19||Q2 FY18|
|Gross Profit Margin||70.59||65.06|
|Return on Assets||-30.58||0.0|
|Return on Equity||-95.07||0.0|
|Debt||Q2 FY19||Q2 FY18|
|Share Data||Q2 FY19||Q2 FY18|
|Shares outstanding (mil)||11.83||11.2|
|Div / share||0.0||0.0|
|Book value / share||11.98||23.3|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||579953.0||2476819.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 0.31 indicates a significant discount versus the S&P 500 average of 3.24 and a significant discount versus the subsector average of 9.60. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. After reviewing these and other key valuation criteria, MELINTA THERAPEUTICS INC proves to trade at a discount to investment alternatives.
|MLNT NM||Peers 26.95||MLNT NM||Peers 17.53|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
MLNT's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
MLNT's P/CF is negative making the measure meaningless.
|MLNT NM||Peers 14.88||MLNT NA||Peers 0.39|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
MLNT's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|MLNT 0.31||Peers 9.60||MLNT 25.65||Peers 516.14|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
MLNT is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, MLNT is expected to significantly trail its peers on the basis of its earnings growth rate.
|MLNT 0.45||Peers 6.55||MLNT 220.33||Peers 8.38|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
MLNT is trading at a significant discount to its subsector on this measurement.
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share.
MLNT has a sales growth rate that significantly exceeds its peers.